Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 15/20 | 1.00 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | CMA1 | P23946 | 2/20 | 0.53 |
| ▸ | PFKFB3 | Q16875 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3147252 | 0.95 | HTR6 (0.90) | HTR6NPSR1L3MBTL1CMA1PFKFB3 | |
| SCHEMBL3147604 | 0.94 | HTR6 (1.00) | HTR6NPSR1L3MBTL1CMA1PFKFB3 | |
| SCHEMBL1575827 | 0.93 | HTR6 (0.87) | HTR6NPSR1L3MBTL1CMA1PFKFB3 | |
| SCHEMBL3156507 | 0.93 | HTR6 (0.91) | HTR6NPSR1L3MBTL1CMA1PFKFB3 | |
| SCHEMBL3148370 | 0.91 | HTR6 (1.00) | HTR6NPSR1L3MBTL1CMA1PFKFB3 | |
| SCHEMBL1997328 | 0.88 | HTR6 (0.80) | HTR6NPSR1L3MBTL1CMA1PFKFB3 | |
| SCHEMBL4969996 | 0.87 | HTR6 (0.77) | HTR6 | |
| SCHEMBL1998470 | 0.87 | HTR6 (0.77) | HTR6NPSR1L3MBTL1CMA1PFKFB3 | |
| SCHEMBL1999791 | 0.87 | HTR6 (0.79) | HTR6NPSR1L3MBTL1CMA1PFKFB3 | |
| SCHEMBL3152564 | 0.86 | HTR6 (1.00) | HTR6NPSR1L3MBTL1CMA1PFKFB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2081600-B1 | Combination of the NMDA- receptor ligand memantine and a compound with 5-HT6 receptor affinity | ESTEVE LABOR DR (ES) | 2012-12-05 | — | — | EP | claimed |
| US-20090264457-A1 | Combination of at least two 5HT6-Ligands | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2009-10-22 | — | — | US | claimed |
| EP-1648445-B1 | INDOL-5-YL SULFONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE 5-HT-6 AS MODULATORS | ESTEVE LABOR DR (ES) | 2009-06-03 | — | — | EP | claimed |
| US-7498328-B2 | Derivatives of sulphonamides, their preparation and use as medicaments | LABORATORIAS DEL DR. ESTEVE, S.A. (ES) | 2009-03-03 | — | — | US | claimed |
| EP-2020230-A1 | Combination of at least two 5-HT6-Ligands | Laboratorios del Dr. Esteve S.A. (ES) | 2009-02-04 | — | — | EP | claimed |
| WO-2009013010-A2 | 5HT6-LIGANDS SUCH AS SULFONAMIDE DERIVATIVES IN DRUG- INDUCED WEIGHT-GAIN | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2009-01-29 | — | — | WO | claimed |
| EP-2018861-A1 | 5HT6-Ligands such as sulfonamide derivatives in drug-induced weight-gain | Laboratorios del Dr. Esteve S.A. (ES) | 2009-01-28 | — | — | EP | claimed |
| EP-1626715-B1 | USE OF SULPHONAMIDE DERIVATIVES FOR THE MANUFACTURE OF A MEDICAMENT FOR THE PROPHYLAXIS AND/OR TREATMENT OF DISORDERS OF FOOD INGESTION | ESTEVE LABOR DR (ES) | 2008-09-10 | — | — | EP | claimed |
| US-20070032520-A1 | Indol-5-yl sulfonamide derivatives, their preparation and their use 5-ht-6 as modulators | LABORATORIOS DEL DR. ESTEVE S.A (ES) | 2007-02-08 | — | — | US | claimed |
| US-20060258653-A1 | Derivatives of sulphonamides, their preparation and use as medicaments | MERCE-VIDAL RAMON | 2006-11-16 | — | — | US | claimed |
| EP-1445252-B1 | SULPHONAMIDE DERIVATIVES, THE PREPARATION THEREOF AND THE APPLICATION OF SAME AS MEDICAMENTS | ESTEVE LABOR DR (ES) | 2006-03-08 | — | — | EP | claimed |
| US-20050065202-A1 | Use of sulphonamide derivatives for the manufacture of a medicament for the prophylaxis and/or treatment of disorders of food ingestion | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2005-03-24 | — | — | US | claimed |
| EP-1445252-A1 | SULPHONAMIDE DERIVATIVES, THE PREPARATION THEREOF AND THE APPLICATION OF SAME AS MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2004-08-11 | — | — | EP | claimed |
| US-20030191124-A1 | Derivatives of sulphonamides, their preparation and use as medicaments | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2003-10-09 | — | — | US | claimed |
| EP-2081600-B1 | Combination of the NMDA- receptor ligand memantine and a compound with 5-HT6 receptor affinity | ESTEVE LABOR DR (ES) | 2012-12-05 | — | — | EP | disclosed |
| US-20120128768-A1 | ACTIVE SUBSTANCE COMBINATION COMPRISING A COMPOUND WITH NPY RECEPTOR AFFINITY AND A COMPOUND WITH 5-HT6 RECEPTOR AFFINITY | LABORATORIOS DEL DR. ESTEVE S.A (ES) | 2012-05-24 | — | — | US | disclosed |
| US-20100120747-A1 | COMBINATION OF A CHOLINESTERASE INHIBITOR AND A COMPOUND WITH 5-HT6 RECEPTOR AFFINITY | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2010-05-13 | — | — | US | disclosed |
| US-20050032791-A1 | Such as N-[3-(2-diethylaminoethyl)-1H-indol-5-yl]-5-chloro-3-methylbenzo[b]thiophene-2-sulphonamide for treating anxiety, depression, cognitive memory disorders and senile dementia, psychosis, infant hyperkinesia (ADHD, attention deficit/hyperactivity disorder) | MERC-VIDAL RAMON (ES) | 2005-02-10 | — | — | US | disclosed |
| EP-1445252-A1 | SULPHONAMIDE DERIVATIVES, THE PREPARATION THEREOF AND THE APPLICATION OF SAME AS MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2004-08-11 | — | — | EP | disclosed |
| US-20030191124-A1 | Derivatives of sulphonamides, their preparation and use as medicaments | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2003-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050065202-A1 | Use of sulphonamide derivatives for the manufacture of a medicament for the prophylaxis and/or treatment of disorders of food ingestion | SULT2A1, STS, MPST | HTR6 886/4885NPSR1 189/4885L3MBTL1 3652/4885 |
| US-20090264457-A1 | Combination of at least two 5HT6-Ligands | HTR6, HTR3B, HTR4 | HTR6 1/4885NPSR1 88/4885L3MBTL1 2836/4885 |
| US-20100120747-A1 | COMBINATION OF A CHOLINESTERASE INHIBITOR AND A COMPOUND WITH 5-HT6 RECEPTOR AFFINITY | HTR6, AANAT, ACHE | HTR6 1/4885NPSR1 60/4885L3MBTL1 4471/4885 |
| US-20050032791-A1 | Such as N-[3-(2-diethylaminoethyl)-1H-indol-5-yl]-5-chloro-3-methylbenzo[b]thiophene-2-sulphonamide for treating anxiety, depression, cognitive memory disorders and senile dementia, psychosis, infant hyperkinesia (ADHD, attention deficit/hyperactivity disorder) | CHAT, SLC6A3, PSEN2 | HTR6 10/4885NPSR1 1122/4885L3MBTL1 2705/4885 |
| US-20120128768-A1 | ACTIVE SUBSTANCE COMBINATION COMPRISING A COMPOUND WITH NPY RECEPTOR AFFINITY AND A COMPOUND WITH 5-HT6 RECEPTOR AFFINITY | HTR6, NPY5R, NPY2R | HTR6 1/4885NPSR1 5/4885L3MBTL1 4752/4885 |
| US-20060258653-A1 | Derivatives of sulphonamides, their preparation and use as medicaments | STS, SULT2A1, MPST | HTR6 3170/4885NPSR1 663/4885L3MBTL1 4813/4885 |
| US-20070032520-A1 | Indol-5-yl sulfonamide derivatives, their preparation and their use 5-ht-6 as modulators | HTR6, HTR5A, TPH1 | HTR6 1/4885NPSR1 58/4885L3MBTL1 4376/4885 |
| US-20030191124-A1 | Derivatives of sulphonamides, their preparation and use as medicaments | STS, SULT2A1, MPST | HTR6 3229/4885NPSR1 692/4885L3MBTL1 4801/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.